Zvakawanikwa (Abstract # 519) zvichaunzwa nhasi na10:00 am ET panguva yekukurumidza abstract session pa2022 American Society for Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium.
Dr. Tanios S. Bekaii-Saab, muongorori weongororo yeKRYSTAL-1, akati, “Gomarara remudumbu mamwe egomarara rinonyanya kupararira uye rinoramba richibatanidzwa nehupenyu husina kunaka pasinei nekufambira mberi kwemazuva ano, kunyanya kune varwere vane GI tumors. Iyo KRASG12C shanduko. Itsva yekiriniki data yakapihwa paASCO GI inoratidza kuti adagrasib, inhibitor yeKRASG12C, yakaratidza kuvimbisa chiitiko chekiriniki muvarwere vane pancreatic cancer uye mamwe mamota eGI. Izvi zvakawanikwa zvinovaka pane zvakambotaurwa zvakanaka adagrasib kiriniki data mune colorectal uye pancreatic cancers, uye zvinokurudzira zvakanyanya, zvichipa kuenderera mberi kuferefetwa kweadagrasib mune ino marongero. "
Pfupiso yeClinical Results
• Kubva munaGunyana 10, 2021, chikamu chevarwere vane GI cancers vane KRASG12C mutation vakanyoreswa muadagrasib monotherapy arm (n=30) vakagamuchira ingangoita mitsetse miviri yekutanga yesystemic anticancer therapies, uye yakave nekutevera kwepakati kwemwedzi 6.3. .
• Pakati pevarwere vanoongororwa (n = 27), chinangwa chekupindura (ORR) chaiva 41% uye chirwere chekudzivirira chirwere (DCR) chaiva 100%. Muvarwere vanoongororwa vane kenza yepancreatic (n = 10), chiyero chekupindura (RR) chaiva 50%, kusanganisira 1 isina kusimbiswa chikamu chemhinduro (PR); iyo yepakati nguva yekupindura (mDOR) yaive mwedzi 7.0, nekutevera kwepakati kwe8.1 mwedzi. Mune varwere vane mamwe maronda eGI (n = 17), RR yaiva 35%, ine maPR maviri asina kusimbiswa; iyo mDOR yaive mwedzi 7.9 muvarwere ava, nekutevera kwepakati kwemwedzi ye6.3.
• The Median progression free Survival (mPFS) muvarwere vane pancreatic cancer yaiva 6.6 mwedzi (95% Confidence Interval, CI: 1.0, 9.7), uye muvarwere vane mamwe maGI tumors, mPFS yaiva mwedzi 7.9 (95% CI 6.90-) 11.30).
• Muchikamu chese chevarwere vane KRASG12C-mutated GI cancers yakaongororwa muboka iri, adagrasib yakatenderwa zvakanaka, ine kuchengetedzwa kwekuchengetedza. Giredhi 3/4 zviitiko zvakashata zvine chekuita nekurapa (TRAEs) zvakaonekwa mu27% yevarwere vakabatwa neadagrasib, vasina maTRAEs anotungamirira pakuregwa kurapwa, uye hapana Giredhi 5 TRAEs yakacherechedzwa.
"Tinotenda kuti adagrasib ine mutsauko wemolecular profile, uye ruzivo rwakaratidzwa kuASCO GI rinowedzera kutsigira kwayo kwakanakisisa-mu-class profile," akadaro Charles M. Baum, MD, Ph.D., muvambi, mutungamiri uye mukuru wekutsvakurudza uye development, Mirati Therapeutics, Inc. "Zvigumisiro zvakaratidza chiitiko chakanaka chekiriniki muvarwere vane KRASG12C-mutated GI cancers vanorapwa ne single agent adagrasib, kunyanya kune avo vane pancreatic cancer uko sarudzo dzisingakwanisi. Tinoramba tichiongorora zvine hukasha kuti adagrasib inhengo imwe chete uye pamwe nemimwe mishonga yegomarara muchirongwa chebudiriro chekubatsira vanhu vazhinji vari kurarama negomarara. "
ZVOKUBVA MUNYAYA INO:
- As of September 10, 2021, the subset of patients with GI cancers harboring a KRASG12C mutation enrolled in the adagrasib monotherapy arm (n=30) received at least two prior lines of systemic anticancer therapies, and had a median follow up of 6.
- Bekaii-Saab, an investigator of the KRYSTAL-1 study, commented, “Gastrointestinal cancers are some of the most common cancers and continue to be associated with poor survival outcomes despite recent advances, especially in patients with GI tumors harboring a KRASG12C mutation.
- We continue to aggressively evaluate adagrasib as a single agent and in combination with other cancer medicines in a broad development plan to help more people living with cancer.
